B2i Digital

The B2i Digital team is pleased to share new commentary from David Schulhof, CEO of the MUSQ ETF MUSQ Music Industry ETF is a B2i Digital Featured Company. See their profile at https://lnkd.in/e27nmGP3. “Many investors still view music as a U.S. and European business. That’s no longer accurate. Today’s growth is coming from Africa, Asia, and Latin America, where streaming access, rising incomes, and strong local talent are transforming music into a truly global industry. Genres like K-pop, Afrobeats, and Latin pop are crossing borders and setting global trends. We also see increased investment in regional infrastructure, including labels, tech platforms, and touring ecosystems. Yes, there are real-world challenges across markets, from regulation to rights management; however, for long-term investors, the opportunity is international. That’s why MUSQ ETF includes companies like HYBE in South Korea, CTS in Germany, Yamaha Corporation in Japan, Tencent Music in China, and Spotify, which continues to expand in emerging markets. We believe the global music economy is entering its next growth phase, and MUSQ is positioned to reflect that shift.” With approximately $23 million in net assets as of early March and a dividend yield of 1%, MUSQ provides investors with diversified exposure to the global music industry, spanning record labels, streaming platforms, concert promoters, music technology firms, and more. To learn more about MUSQ, visit https://musqetf.com. For investor inquiries, please contact info@musq.com. #MUSQ #MusicIndustry #ETF #B2iDigital #EmergingMarkets #GlobalMusic *Past performance is not indicative of future results. Investors should conduct their own research before making investment decisions. David Shapiro, CEO of B2i Digital, personally purchased and owns shares in MUSQ. This post is not an offer to solicit the sale of any security and is not a recommendation to buy any security.

Unicycive Therapeutics (Nasdaq: UNCY) released new patient-reported outcomes data today, underscoring the challenges dialysis patients face with current phosphate binders and highlighting the potential of investigational candidate oxylanthanum carbonate (OLC) to reduce pill burden and improve adherence in patients with hyperphosphatemia. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/eSiwcGjb. The company cited several developments, including: - Results from the pivotal Phase 2 UNI-OLC-201 trial showed that OLC reduced pill burden by 50%, improved adherence, and was preferred by 79% of patients compared to their previous phosphate binder. - A separate survey conducted in collaboration with the National Kidney Foundation identified pill burden and large tablet size as key barriers to adherence. These findings will be presented today at the NKF Spring Clinical Meetings in Boston. - Unicycive’s NDA for OLC is under FDA review, with a PDUFA Target Action Date of June 28, 2025. Dr. Pablo Pergola, Principal Investigator, noted, “These new patient-reported outcomes underscore the potential of OLC to enhance adherence, reduce treatment burden and improve patient satisfaction. OLC could be a welcome new phosphate binder choice for patients with hyperphosphatemia due to its favorable tolerability, small, easy-to-swallow size and low pill burden.” See the full news release here: https://lnkd.in/eJz52bdA The global market opportunity for treating hyperphosphatemia is projected to be over $2.28 billion, with North America accounting for over $1 billion. Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio, including issued patents on composition of matter with exclusivity until 2031 and the potential for patent term extension until 2035. Unicycive Therapeutics is a clinical-stage biotechnology company focused on innovative therapies for kidney diseases. Its lead asset, OLC, is a next-generation phosphate binder in development for hyperphosphatemia, utilizing proprietary nanoparticle technology to reduce pill burden. The company is also advancing UNI-494, a novel treatment for acute kidney injury. Led by CEO Dr. Shalabh Gupta, MD and a highly experienced executive team, including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, Unicycive is dedicated to its mission of addressing unmet needs in kidney disease treatment. Please visit Unicycive (https://unicycive.com/) and B2i Digital (https://b2idigital.com/) to learn more and follow Unicycive’s journey as the company advances innovative treatments for kidney disease. #Unicycive #UNCY #B2iDigital #KidneyDisease #PatientOutcomes

OS Therapies (NYSE-A: OSTX) announced new positive data for OST-HER2 in treating unresected osteosarcoma in dogs. The combination of OST-HER2 and palliative radiation resulted in tumor control, delayed metastases, and survival of more than 500 days in one-third of the study animals. The data suggest a potential future role for OST-HER2 as a frontline therapy in human osteosarcoma before surgery or chemotherapy. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/epFNRZQB. Highlights from today’s announcement include: - In a study of 15 dogs with unresected primary osteosarcoma, treatment with OST-HER2 and palliative radiation led to tumor arrest and prolonged survival without surgery or chemotherapy. - Peer-reviewed data published in Molecular Therapy showed that strong immune responses to OST-HER2 correlated with long-term survival in dogs with resected tumors, supporting potential use in humans. - OST-HER2 was well tolerated in both studies and may represent a significant advance in controlling metastatic disease and prolonging survival. CEO Paul Romness noted, “It has been my dream since founding the Company that OST-HER2 could potentially change the standard of care in osteosarcoma, potentially limiting the need for amputation or surgical resection of the primary tumor. With today’s data, we believe we are taking the first steps towards this given that our Comparative Oncology approach, as a result of the 96% genetic homology between human and canine osteosarcoma, leads us to believe there is significant potential for this canine data to translate into humans in the treatment of frontline and primary metastatic osteosarcoma, similarly to how it has in recurrent, fully-resected, lung metastatic osteosarcoma.” The company plans to pursue conditional approval from the USDA for OST-HER2's updated formulation in canine use later this year. Read the full release: https://lnkd.in/ew3YJEyb OS Therapies is a clinical-stage oncology company focused on developing a new class of listeria-based immunotherapy candidates for osteosarcoma and other solid tumors. Its lead candidate, OST-HER2, has received RPDD, Orphan Drug, and Fast Track designations and demonstrated a statistically significant survival benefit in a Phase 2b clinical trial. The company plans to submit a BLA to the FDA in 2025. Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers. Learn more about OS Therapies’ work at https://lnkd.in/eMc3JKG6 and visit B2i Digital for updates.

OS Therapies (NYSE-A: OSTX) announced today that it has completed the acquisition of the listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals, positioning OS Therapies as the world leader in listeria-based cancer immunotherapies. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/epFNRZQB The acquisition significantly expands OS Therapies’ clinical pipeline with three new cancer immunotherapy candidates: - OST-AXAL (previously AXAL/ADXS/HPV) for Human Papilloma Virus (HPV)-associated cancers (completed 1 of 2 Phase 3 trials) - OST-503 (previously ADXS-503) for Non-Small Cell Lung Cancer (NSCLC) & Glioblastoma (positive Phase 2 data in NSCLC) - OST-PSA (previously ADXS-504/ADXS31142) for Prostate Cancer Additionally, the Company has added 8 un-named pre-clinical immunotherapy candidates targeting over 30 cancers. New manufacturing-based intellectual property protects the listeria-based platform and candidates into 2040. “We are thrilled to have now consolidated all of the intellectual property for the listeria cancer immunotherapy platform into OS Therapies, positioning us to fully expand it in the years ahead and improve the standard of care across cancer treatment in the years ahead,” said Paul Romness, CEO of OS Therapies. The Company is poised to become a new commercial category of immunotherapy in oncology upon approval of its lead asset OST-HER2 to prevent recurrence in fully-resected, lung metastatic osteosarcoma, targeted for year-end 2025. Upon approval, the Company will become eligible to receive a Priority Review Voucher, currently valued at $150 million. According to Nova One Advisor, the global cancer immunotherapy market size was valued at $126 billion in 2023 and is projected to surpass around $296 billion by 2033. OS Therapies is a clinical-stage oncology company focused on identifying, developing, and commercializing a new class of immunotherapy candidates for solid tumors, beginning with osteosarcoma. The Company’s lead asset, OST-HER2, has received Rare Pediatric Disease Designation from the FDA and demonstrated positive data in a Phase 2b clinical trial. The company intends to submit a BLA Accelerated Approval request to the FDA in the third quarter of 2025. Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers. Learn more about OS Therapies’ work at https://lnkd.in/eMc3JKG6 and visit B2i Digital for updates. For investor-related questions, please visit OS Therapies’ Investor Relations page or email irpr@ostherapies.com.

🎤 Lady Gaga isn’t just a pop icon — she’s an economic engine. From music and film to fashion and tech, every Gaga era moves culture and markets. Album drops, sold-out tours, even her choice of piano — they all may create ripple effects across multiple industries. But what about the businesses behind the Gaga effect? 👉 Enter the MUSQ Global Music Industry Index ETF (MUSQ) — a music industry ETF that includes companies like Spotify, Apple, Live Nation, Universal Music Group, Yamaha, and more. These are the platforms, promoters, and producers supporting artists like Gaga — and potentially benefiting from their global influence. With her new album Mayhem generating buzz, it’s a timely reminder of how pop culture and business are more connected than ever. Click here to learn more: https://lnkd.in/eg-xbqNJ 🎶 This is the business behind the beat. View MUSQ holdings: musqetf.com/musq

CEO Paul Romness and CBO Gerald Commissiong, of B2i Digital's Featured Company OS Therapies, recently attended the premiere of director and producer Stephen Latham’s latest film, “Shelter Me: The Cancer Pioneers,” which features our OST-HER2 #immunotherapy. Steven’s film is an inspiring story that the OS Therapies team is extremely proud to be a part of. OST-HER2 is an immunotherapy that leverages the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the #HER2 protein. The film details groundbreaking clinical trials in #comparativeoncology, in which treatments utilized for dogs with cancer are now being applied to human patients. Leading scientists from the National Cancer Institute (NCI) / The National Institutes of Health, the University of Pennsylvania, the University of Illinois, the University of Wisconsin-Madison, and Colorado State University are all featured as well. You can see the full Stephen Latham Productions film on PBS and the network’s app in May. Learn more about “Shelter Me” here: www.shelterme.tv Powered by Petco Love #Osteosarcoma #OSTX $OSTX #CancerResearch #OSTHER2

“As a physician, I could take care of a few patients at a time, say five to 10 patients in a day, which translates to a few thousand patients in a year. But if you expand that a little bit more broadly today, what we do at Unicycive or in the biotech industry has the potential to impact millions and millions of patients. So, in some ways, what I used to do then is similar to what I’m doing today.” Our founder and CEO Shalabh Gupta, MD recently sat down with Xtalks reporter Ayesha Rashid, PhD to discuss his passion for improving patient outcomes and the work he does at Unicycive to address significant needs in kidney disease. Listen to their full discussion at https://buff.ly/1y8Zzbw

Innovation 🤝🏽 Investment. We'll be discussing both at the 24th Annual Needham Virtual Healthcare Conference. We're looking forward to the conversation and collaboration about what’s next in healthcare innovation! #NeedhamConference #BiotechInvestment #HealthcareInnovation #Unicycive

We think about a PDUFA date as the mile marker where we go from research and development to bringing our solutions to patients. By having a PDUFA date assigned for our lead asset, Oxylanthanum Carbonate (OLC), we're one step closer to making an immediate impact in the lives of kidney disease patients.

OS Therapies (NYSE-A: OSTX) announced that it has formally requested a meeting with the FDA’s Center for Biologics Evaluation and Research (CBER) to gain alignment on clinical endpoints required for Breakthrough Therapy Designation (BTD) and Accelerated Approval via a conditional BLA for candidate OST-HER2 in the prevention or delay of recurrence of fully resected, lung metastatic osteosarcoma. This meeting follows the FDA’s feedback on a prior BTD request and represents an important step in clarifying data requirements for potential expedited review. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/epFNRZQB Robert Petit, Chief Medical & Scientific Officer of OS Therapies, commented, “We are excited to meet with the FDA – and commence market access discussions - the goal of receiving Accelerated Approval for a Biologics License Application of OST-HER2 in the prevention or delay of recurrence lung metastatic osteosarcoma by year-end 2025. We believe that we have identified the comparator data necessary to address the comments from FDA regarding our prior BTD request. We expect this data will also be able to support our application for Accelerated Approval. Our clinical and regulatory teams are diligently preparing for the meeting and the subsequent BLA submission that is targeted to begin after the public release of additional clinical trial data at MIB Factor in June.” See the full news release at https://lnkd.in/eyGherM8 As a reminder, OS Therapies is holding an analyst day today in New York at the New York Stock Exchange. For more information, please see https://lnkd.in/e5QgCVdN. OS Therapies is a clinical-stage oncology company focused on identifying, developing, and commercializing treatments for osteosarcoma and other solid tumors. The company’s lead product candidate, OST-HER2, leverages Listeria-based immunotherapy to stimulate a robust immune response against HER2-expressing cancer cells. Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers. Learn more about OS Therapies’ work at https://lnkd.in/eMc3JKG6 and visit B2i Digital for updates. For investor-related questions, please visit OS Therapies’ Investor Relations page or email irpr@ostherapies.com. #OSTherapies #Immunotherapy #B2iDigital #Osteosarcoma #NYSEAnalystDay